DeltaPoint Selected As The Oregon Entrepreneurs Network Angel Oregon 2010 Investment Winner

“ Company Secures $170,000 of Initial Investment Capital ”

Share on            

Email Friend     Contact Author

(iTechWire.Org) – DeltaPoint, Inc., announced today that it was selected as the winner of OEN’s Angel Oregon 2010 Launch Stage investment competition and will receive $170,000 in operating capital. OEN’s Angel Oregon is the Northwest’s premier deal flow and networking event for Oregon and SW Washington-based angel investors and early-stage entrepreneurs. This year’s finalist companies were selected from nearly 50 entrants, based throughout Oregon and Southwest Washington, that applied to compete at OEN’s Angel Oregon 2010. A rigorous process was undertaken by the 39-member panel of angel investors to select DeltaPoint as the Launch Stage company winner.

DeltaPoint is a healthcare technology company commercializing cancer diagnostic software algorithms licensed from Oregon Health & Sciences University. The company is developing medical imaging data analysis software designed to provide physicians with quantitative information that will help them more reliably find cancers, better plan biopsies and more effectively treat cancer patients. DeltaPoint is focusing first on helping to address the immense challenges associated with detecting, diagnosing and treating breast cancer. “DeltaPoint was viewed by OEN’s Angel Oregon investors as an exceptional company with the potential to impact millions of people facing the prospect of cancer, as well as a company with the potential to generate significant returns to early investors,” said Angela Jackson, AB Jackson Group and Chair of OEN’s Angel Oregon 2010. “We are excited to be part of the company’s journey.”

“We are honored to have been selected by OEN’s Angel Oregon investors and value the tremendous confidence and support we received from this amazing group,” said Richard A. Lazar, founder and CEO of DeltaPoint. “OEN’s Angel Oregon 2010, LLC’s investment represents a great start to our fundraising goals and will enable DeltaPoint to accelerate its regulatory, product development and market education efforts.”

Detecting and diagnosing breast cancer remains a very difficult task for physicians. Medical imaging is used to screen over 40 million women per year in the U.S. for breast cancer. Of these, over 750,000 women are referred for biopsy to evaluate suspicious lesions. Between two-thirds and three-quarters of these biopsies are found to be benign. Between three and nine percent of these biopsies fail to identify existing cancers. DeltaPoint aims to help solve these problems by providing physicians with information that will help them more reliably find cancers, better plan biopsies and more effectively treat cancer patients.